Strom Carrie C's Form 4 filing
AbbVie Inc. (ABBV) · filed Feb 21, 2023
- Accession no.
- 0001415889-23-002946
- Filed
- Feb 21, 2023
- Trade date
- Feb 16-21, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 10 non-derivative transactions and 3 derivative transactions. Open-market sales total $4.31M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Strom Carrie CCIK 0001811896 | Officer (SVP & PRES GLOBAL ALLERG AESTH) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 | Common Stock, $0.01 par value | AGrant or awardAcquired | +6,546 | $0.00 | $0 | 47,209 | Direct | |
| Feb 16, 2023 | Common Stock, $0.01 par value | AGrant or awardAcquired | +5,074 | $0.00 | $0 | 52,283 | Direct | |
| Feb 21, 2023 | Common Stock, $0.01 par value | MOption exerciseAcquired | +7,809 | $56.93 | +$444,566.37 | 60,092 | Direct | |
| Feb 21, 2023 | Common Stock, $0.01 par value | MOption exerciseAcquired | +6,370 | $67.25 | +$428,382.5 | 66,462 | Direct | |
| Feb 21, 2023 | Common Stock, $0.01 par value | SSaleDisposed | −5,615 | $150.71F3 | −$846,236.65 | 60,847 | Direct | |
| Feb 21, 2023 | Common Stock, $0.01 par value | SSaleDisposed | −7,780 | $151.28F4 | −$1,176,958.4 | 53,067 | Direct | |
| Feb 21, 2023 | Common Stock, $0.01 par value | SSaleDisposed | −6,533 | $150.74F5 | −$984,784.42 | 46,534 | Direct | |
| Feb 21, 2023 | Common Stock, $0.01 par value | SSaleDisposed | −7,646 | $151.29F6 | −$1,156,763.34 | 38,888 | Direct | |
| Feb 21, 2023 | Common Stock, $0.01 par value | SSaleDisposed | −567 | $150.78F7 | −$85,492.26 | 38,321 | Direct | |
| Feb 21, 2023 | Common Stock, $0.01 par value | SSaleDisposed | −400 | $151.34F8 | −$60,536 | 37,921 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 | Common Stock | AGrant or awardAcquired | +16,205 | $0.00 | $0 | 16,205 | Direct | |
| Feb 21, 2023 | Common Stock | MOption exerciseDisposed | −7,809 | $56.93 | −$444,566.37 | 0 | Direct | |
| Feb 21, 2023 | Common Stock | MOption exerciseDisposed | −6,370 | $67.25 | −$428,382.5 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.10, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.15 to $151.42, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).